The Board at its meeting held today, May 14, 2026, had 1. Approved the Audited standalone and consolidated financial results of the Company for the year ended March 31, 2026, along with ....
CAPLIPOINT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.5 pts more than Nifty Smallcap 250 and 10.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Caplin Point Laboratories reported strong FY26 results with consolidated revenue of ₹2,303 Crores, up 13.2% YoY. Net profit grew 20.1% to ₹650 Crores driven by 28.7% growth in US market revenue to ₹471 Crores. The Board declared an interim dividend of ₹4 per share (200% on face value of ₹2). Auditors M/s Brahmayya & Co issued an unmodified (clean) opinion on both standalone and consolidated financials. The company has liquid assets of ₹2,726 Crores and free cash reserves of ₹1,471 Crores. One step-down subsidiary reported unaudited losses of ₹3.33 Crores for the year.
Strong earnings growth and dividend declaration are positive for shareholders. The clean audit opinion removes any concerns about financial reporting quality. High cash reserves provide flexibility for future growth investments or additional shareholder returns.